MRSA

IDSA MRSA Guidelines

IDSA MRSA GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/88040

Contents of this Issue

Navigation

Page 7 of 17

Selecting a Treatment Regimen Table 1. Recommendations for the Treatment of MRSA (cont'd) Manifestation Treatments Management/ Surgery Bacteremia and Infective Endocarditis Bacteremia|| A clinical assessment to identify the source and extent of the infection with elimination and/ or debridement of other sites of infection should be conducted (A-II). Echocardiography is recommended for all adult patients with bacteremia. Transesophageal echocardiography (TEE) is preferred over transthoracic echocardiography (TTE). Vancomycin‡§ Daptomycin‡ (Cubicin® 15-20 mg/kg/dose IV q8-12h ) 6 mg/kg/dose IV daily of Therapy Duration Antibiotics Agent (Brand) Adult Dose Treat for 2-6 weeks.† Persistent bacteremia Please see Persistent MRSA Bacteremia and Vancomycin Treatment Failures in Adults (page 15) Infective endocarditis, native valve Infective endocarditis, prosthetic valve Repeat blood cultures 2-4 days aſter initial positive cultures and as needed thereaſter are recommended to document clearance of bacteremia. Treat for 6 weeks. Same as for bacteremia Treat for ≥ 6 weeks plus gentamicin for 2 weeks. † Based on the extent of disease and the patient's clinical response. Vancomycin‡§ and Gentamicin‡ and Rifampin ‡ Adjust dose for renal impairment – see Prescribing Information for renal dosing. 15-20 mg/kg/dose IV q8-12h 1 mg/kg/dose IV q8h 300 mg PO/IV q8h 6

Articles in this issue

Archives of this issue

view archives of MRSA - IDSA MRSA Guidelines